On November 3, 2025, Sarepta Therapeutics reported that its Phase 3 ESSENCE trial for Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 did not meet the primary endpoint, though ...
The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.
TipRanks on MSN
Sarepta Stock’s (SRPT) Painful Plunge! Is There Any Hope Left for Investors after DMD Trial Miss?
Shares of Sarepta Therapeutics ($SRPT) plunged after the company reported disappointing results from a key trial of its Duchenne muscular ...
Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...
The firm's stock tumbled on the news, dropping from $24.45 per share at market close Monday to $15.24 per share when the market opened Tuesday.
Major U.S. equities indexes were lower at midday Tuesday, with Palantir Technologies leading tech stocks lower.
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...
Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance. Though the biotech ...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" ...
Sarepta Therapeutics' shares plunged nearly 30% on Tuesday as the failure of two of its approved drugs in a key trial and ...
Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...
Sarepta Therapeutics' shares plunged nearly 40% in premarket trading on Tuesday as failure of two of its approved drugs for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback